imidapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin-converting enzyme inhibitors	1424	89371-37-9

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

imidapril hydrochloride
tanatril
imidapril
TA-6366
imidapril HCl

Molecular weight: 405.45
Formula: C20H27N3O6
CLOGP: 1.53
LIPINSKI: 0
HAC: 9
HDO: 2
TPSA: 116.25
ALOGS: -2.96
ROTB: 10

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1993	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	46.84	37.90	20	478	76020	50528606

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	35.94	29.91	16	769	24659	29549083

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	61.37	28.66	38	1446	132335	64364913
Cerebral infarction	51.54	28.66	23	1461	41021	64456227
Hepatic function abnormal	50.21	28.66	26	1458	64287	64432961
Renal impairment	41.38	28.66	30	1454	134987	64362261
Interstitial lung disease	37.64	28.66	25	1459	97707	64399541
Embolic stroke	31.90	28.66	10	1474	6701	64490547

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09AA16	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain
MeSH PA	D000806	Angiotensin-Converting Enzyme Inhibitors
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors
CHEBI has role	CHEBI:35457	ACE inhibitor
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:49103	drug metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.49	acidic
pKa2	4.83	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	INHIBITOR	IC50	5		CHEMBL	SCIENTIFIC LITERATURE

External reference:

ID	Source
D01549	KEGG_DRUG
89396-94-1	SECONDARY_CAS_RN
C0165703	UMLSCUI
CHEBI:135654	CHEBI
CHEBI:141520	CHEBI
CHEMBL317094	ChEMBL_ID
DB11783	DRUGBANK_ID
C065166	MESH_SUPPLEMENTAL_RECORD_UI
5464343	PUBCHEM_CID
6377	IUPHAR_LIGAND_ID
C078006	MESH_SUPPLEMENTAL_RECORD_UI
6378	IUPHAR_LIGAND_ID
6394	INN_ID
89371-44-8	SECONDARY_CAS_RN
BW7H1TJS22	UNII
5464344	PUBCHEM_CID
259335	RXNORM
007791	NDDF
007792	NDDF
395741003	SNOMEDCT_US
395984005	SNOMEDCT_US
426163004	SNOMEDCT_US
C0246977	UMLSCUI
CHEMBL99701	ChEMBL_ID
7209	INN_ID
WUU07Y30IA	UNII

Pharmaceutical products:

None